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Abstract
Background: In primary care, it is often difficult to diagnose cervical myelopathy. However, a delay in treatment
could cause irreversible aftereffects. With a brief and effective self-administered questionnaire for cervical
myelopathy, cervical myelopathy may be screened more easily and oversight may be avoided. As there is presently
no screening tool for cervical myelopathy, the aim of this study was to develop a self-administered questionnaire
for the screening of cervical myelopathy.
Methods: A case-control study was performed with the following two groups at our university hospital from
February 2006 to September 2008. Sixty-two patients (48 men, 14 women) with cervical myelopathy who
underwent operative treatment were included in the myelopathy group. In the control group, 49 patients (20 men,
29 women) with symptoms that could be distinguished from those of cervical myelopathy, such as numbness,
pain in the upper extremities, and manual clumsiness, were included. The underlying conditions were diagnosed
as carpal tunnel syndrome, cubital tunnel syndrome, thoracic outlet syndrome, tarsal tunnel syndrome, diabetes
mellitus neuropathy, cervical radiculopathy, and neuralgic amyotrophy. Twenty items for a questionnaire in this
study were chosen from the Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire,
which is a new self-administered questionnaire, as an outcome measure for patients with cervical myelopathy. Data
were analyzed by univariate analysis using the chi-square test and by multiple logistic regression analysis.
According to the resulting odds ratio, b-coefficients, and p value, items were chosen and assigned a score.
Results: Eight items were chosen by univariate and multiple logistic regression analyses and assigned a score. The
Hosmer-Lemeshow statistic showed p = 0.805. The area under the receiver operation characteristic curve was 0.86.
The developed questionnaire had a sensitivity of 93.5% and a specificity of 67.3%.
Conclusions: We successfully developed a simple self-administered questionnaire to screen for cervical
myelopathy.
Background
Cervical myelopathy is caused by mechanical and
dynamic compression of the spinal cord and develop-
mental spinal canal stenosis [1]. Patients with cervical
myelopathy have various symptoms, such as numbness,
pain, hypoesthesia and weakness of the extremities, pain
and stiffness of the neck, manual clumsiness, walking dis-
turbance, and urinary disturbance [2-5]. Numbness of
the upper extremities is one of the chief symptoms in
cervical myelopathy and patients with cervical myelopa-
thy who have this numbness frequently consult a general
outpatient clinic or a primary care practitioner. Upper
extremity numbness may also be caused by entrapment
neuropathy, such as carpal and cubital tunnel syndromes.
Therefore, diagnosis of cervical myelopathy in such
patients is sometimes difficult and costly in primary care.
To make an accurate diagnosis, much data must be
examined, such as the case history, physical examination
including a neurological examination, and imaging tests.
Furthermore, misdiagnosis and delayed treatment may
result in irreversible consequences, such as paralysis,
urinary disturbance, and walking disturbance. Therefore,
accurate diagnosis and treatment by a specialist are
needed for a good outcome. If there were a brief, self-
administered questionnaire for cervical myelopathy
screening, patients could answer it easily while waiting
for a primary care or outpatient clinic consultation.
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questionnaire to screen for cervical myelopathy. The aim
of this study was to develop a self-administered question-
naire to screen for cervical myelopathy.
Methods
Ethical considerations
The present study was approved by the institutional
review board of Fukushima Medical University and was
conducted in compliance with ethical standards. All par-
ticipants gave their written informed consent.
Objective
One hundred eleven patients were enrolled in this case-
control study (Table 1). In the myelopathy group,
62 patients (48 men, 14 women) with a diagnosis of cer-
vical myelopathy who underwent surgery at Fukushima
Medical University Hospital from February 2006 to Sep-
tember 2008 were included. Cervical myelopathy was
secondary to a herniated disc in 5 patients, spondylosis
in 32 patients, ossification of the posterior longitudinal
ligament in 22 patients, and a combination of these in
three patients. To develop a questionnaire to screen for
cervical myelopathy, the control group comprised
patients with upper extremity symptoms not caused by
cervical myelopathy. Patients with dementia, a history of
cervical operations, rheumatoid arthritis, infectious
spondylitis, cervical myotrophy, tumor, spinal injury,
cerebral infarction, and trauma were excluded.
Questionnaire
There were 20 candidate items for the questionnaire
(Table 2), all taken from the Japanese Orthopaedic Asso-
ciation Cervical Myelopathy Evaluation Questionnaire
(JOACMEQ), a new self-administered questionnaire used
as an outcome measure for patients with cervical myelo-
pathy [6-10]. JOACMEQ is a questionnaire produced by
identifying items regarded by specialists as important for
the evaluation of cervical myelopathy and performing sta-
tistical selection. Its validity and reliability have already
been demonstrated [6-9]. JOACMEQ consists of ques-
tions about the functional capacity of the cervical spine,
physical function of the upper and lower extremities, and
bladder function, which might be disturbed by cervical
myelopathy, and items for quality of life (QOL). Because
QOL items might be useless for screening, the QOL
items were not included. To make the questionnaire easy
for respondents to answer, the questions were changed
to be answered “yes” or “no”. Respondents were asked to
consider their physical condition in the preceding week.
If a respondent’s condition had changed depending on
the day or the time, the respondent was asked to identify
Table 1 Demographic data of the Myelopathy and
Control groups
Control group
(n = 49)
Myelopathy group
(n = 62)
Mean age
(y (SD)
62.1 (13.3) 62.3 (13.8)
Male (%) 20 (38.8) 48 (77.4)
Female (%) 29 (61.2) 14 (22.6)
Diagnosis (%) CTS 34 (69.4) CSM 32 (51.6)
CuTS 9 (18.4) CDH 5 (8.1)
CTS + CuTS 1 (2.0) OPLL 22 (35.5)
CTS + DN 1 (2.0) combination 3 (4.8)
TTS + DN 1 (2.0)
TOS 1 (2.0)
Cervical
radiculopathy
1 (2.0)
Neuralgic
amyotrophy
1 (2.0)
CTS: Carpal Tunnel Syndrome
CuTS: Cubital Tunnel Syndrome
DN: Diabetic Neuropathy
TTS: Tarsal Tunnel Syndrome
TOS: Thoracic Outlet Syndrome
CSM: Cervical Spondylotic Myelopathy
CDH: Cervical Disc Herniation
OPLL: Ossification of Posterior Longitudinal Ligament
Table 2 Candidates from the JOACMEQ questionnaire
Q1-1 While in the sitting position, can you look up at the ceiling
by tilting your head upward?
Q1-2 Can you drink a glass of water without stopping despite
the neck symptoms?
Q1-3 While in the sitting position, can you turn your head
toward the person who is seated to the side but behind
you and speak to that person while looking at his/her
face?
Q1-4 Can you look at your feet when you go down the stairs?
Q2-1 Can you fasten the front buttons of your blouse or shirt
with both hands?
Q2-2 Can you eat a meal with your dominant hand using a
spoon or a fork?
Q2-3 Can you raise your arm? (Answer for the weaker side.)
Q3-1 Can you walk on a flat surface?
Q3-2 Can you stand on either leg without holding onto
something? (or the need to support yourself)
Q3-3 Do you have difficulty climbing the stairs to one floor
above?
Q3-4 Do you have difficulty bending forward, keeling, and
stopping?
Q3-5 Do you have difficulty walking for 15 minutes?
Q4-1 Do you have urinary incontinence?
Q4-2 Do you go to the bathroom at night?
Q4-3 Do you have a feeling of residual urine in your bladder
after voiding?
Q4-4 Can you initiate (start) your urine stream immediately
when you want to void?
Q5 Do you have neck pain, shoulder pain, and neck stiffness?
Q6 Do you have chest tightness?
Q7 Do you have pain or numbness in the upper extremity?
Q8 Do you have pain or numbness from chest to forefoot?
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worst condition”. Patients in the myelopathy group
answered the questionnaire a day before surgery. In the
control group, outpatients satisfying the criteria answered
the questionnaire prospectively in the outpatient clinic.
The answers to these items were compared between the
two groups.
Statistical analyses
First, the chi-square test was used for univariate analysis.
Odds ratios (ORs), 95% confidence intervals (95%CI),
and p values were calculated. Items with ORs ≥2a n dp
values < 0.05 were included in the multiple logistic
regression analysis. Next, b-coefficients, adjusted ORs,
95%CI, and p values were calculated. Items with ORs
< 2 were removed.
Using a regression coefficient-based scoring system, a
score-based questionnaire to screen patients with cervical
myelopathy was developed based on the multiple logistic
regression equations. The calibration was evaluated using
the Hosmer-Lemeshow chi-square statistic (p > 0.05 for
all models); p ≥ 0.05 supports the goodness of fit.
To generate a simple integer-based point score for each
predictor variable, scores were assigned by dividing the
b-coefficient by two-fifths of the sum of the two smallest
coefficients in the model and rounding up to the nearest
integer. The overall risk score for each patient was calcu-
lated by summing the scores of each component.
The discrimination ability of the models was assessed
b yt h ea r e au n d e rt h er e c e i v e r operating characteristic
(ROC) curve. Discriminatory power is the ability to
identify cervical myelopathy. An area of 1.00 under the
ROC curve indicates perfect discrimination, whereas
an area of 0.50 indicates complete absence of discrimi-
nation. The calibration was also evaluated by compar-
ing the prevalence of cervical myelopathy in the score.
To examine the performance of the questionnaire, the
sensitivity, specificity, positive likelihood ratio, and
negative likelihood ratio were calculated. This ques-
tionnaire needed a high sensitivity and a low negative
likelihood ratio (< 0.1) for screening. The positivity cri-
terion for the presence of cervical myelopathy was
defined as the point with sufficiently high sensitivity
for screening. All statistical analyses were performed
using the SPSS software program (version 11.0.1) run-
ning on Microsoft Windows Vista (Microsoft, Red-
mond, WA, USA).
Table 3 Univariate analysis for factors from the
questionnaire
Positive rate
Item Control Myelopathy OR 95% CI p value
Q1-1 2.08 11.29 5.98 0.71 - 50.39 0.135
Q1-2 18.75 22.58 1.26 0.50 - 3.23 0.646
Q1-3 14.58 36.07 3.30 1.27 - 8.60 0.016 *
Q1-4 8.33 16.67 2.20 0.64 - 7.51 0.255
Q2-1 14.58 32.26 2.79 1.07 - 7.30 0.044 *
Q2-2 6.25 11.29 1.91 0.47 - 7.81 0.509
Q2-3 14.58 4.84 0.30 0.073 - 1.22 0.10
Q3-1 2.08 9.68 5.04 0.59 - 43.3 0.108
Q3-2 12.50 44.83 5.69 2.09 - 19.46 < 0.001 *
Q3-3 17.02 80.65 20.31 7.57 - 54.54 < 0.001 *
Q3-4 28.26 74.19 7.30 3.10 - 17.21 < 0.001 *
Q3-5 15.22 74.19 16.02 5.98 - 42.91 < 0.001 *
Q4-1 10.64 38.71 5.31 18.40 - 15.29 0.001 *
Q4-2 61.70 73.77 1.75 0.77 - 3.96 0.213
Q4-3 23.91 55.74 4.01 1.72 - 9.33 0.001 *
Q4-4 10.64 54.84 10.20 3.56 - 29.25 < 0.001 *
Q5 51.02 89.83 8.48 3.08 - 23.36 < 0.001 *
Q6 2.08 32.76 22.90 2.93 - 178.79 < 0.001 *
Q7 66.67 98.31 29.00 3.68 - 228.87 < 0.001 *
Q8 20.83 79.66 14.88 5.80 - 38.172 < 0.001 *
*p < 0.05 and OR ≥ 2, OR: odds ratio, CI: confidence interval
Table 4 Multivariate analysis
Item b-coefficient Adjusted OR 95% CI p value
Q1-3 -1.79 0.17 0.009 - 3.11 0.23
Q2-1 0.482 1.619 0.13 - 19.78 0.71
Q3-2 -0.79 0.45 0.025 - 8.14 0.59
Q3-3 2.96 19.24 0.88 - 420.71 0.06 *
Q3-4 -1.04 0.36 0.15 - 8.49 0.52
Q3-5 1.78 5.93 0.52 - 67.65 0.15 *
Q4-1 0.67 1.95 0.20 - 18.59 0.56
Q4-3 1.68 5.35 0.85 - 33.57 0.07 *
Q4-4 1.83 6.26 0.63 - 62.63 0.02 *
Q5 1.68 5.35 0.62 - 46.10 0.13 *
Q6 1.82 6.11 0.39 - 96.09 0.20 *
Q7 3.24 25.62 0.019 - 35024.02 0.37 *
Q8 1.49 4.43 0.79 - 24.88 0.09 *
*OR ≥ 2
Table 5 Scoring
Item b-
coefficient
Adjusted
OR
95% CI p
value
Assigned
score
Q3-3 2.06 7.88 1.20 - 51.59 0.031 2
Q3-5 1.07 2.92 0.40 - 21.16 0.29 1
Q4-3 1.41 4.09 0.89 - 18.77 0.07 1
Q4-4 1.30 3.68 0.61 - 22.28 0.16 1
Q5 1.87 6.50 0.95 - 44.31 0.056 2
Q6 1.54 4.65 0.35 - 61.71 0.24 2
Q7 2.78 16.14 0.087 -
3003.79
0.30 3
Q8 1.31 3.70 0.82 - 16.63 0.019 1
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Univariate analysis
The 20 items were subjected to univariate analysis and
the OR was calculated for each item (Table 3). Thirteen
items had an OR ≥ 2 and p < 0.05: Q1-3, Q2-1, Q3-2,
Q3-3, Q3-4, Q3-5, Q4-1, Q4-3, Q4-4, Q5, Q6, Q7, and
Q8. Most items representing lower leg function, bladder
function, and subjective symptoms were included. In
contrast, upper extremity items were not significant,
which suggested that patients in both groups had upper
extremity disorders. Thus, the 13 items with an OR ≥ 2
and p < 0.05 were chosen for the next step.
Multiple logistic regression analysis
On multiple logistic regression analysis using the 13
items (Table 4), the b-coefficients, adjusted ORs, 95%CI,
and p values were calculated. Eight of the thirteen items
had an adjusted OR ≥ 2: Q3-3, Q3-4, Q4-3, Q4-4, Q5,
Q6, Q7, and Q8. Multiple logistic regression analysis
was again performed with these eight items. For the
final model, the Hosmer-Lemeshow statistic showed p =
0.805, indicating good calibration.
Assignment of scores
According to the calculated b-coefficients, score values
were defined for the eight items. An integer score
derived from the b-coefficients was assigned to the iden-
tified items (Table 5). For each patient, all applicable
score values were summed up to attain a total score for
the patient. The sum of the risk scores for each patient
r a n g e df r o m0t o1 3( F i g u r e1 ) . Finally, a self-adminis-
tered questionnaire was developed (Table 6). The area
under the ROC curve was 0.86; thus, the model had
good discriminatory power (Figure 2).
Setting of the cut-off point
The positivity cut-off point was defined as 6, because
the sum of the sensitivities was sufficient for screening.
Given that the positivity criterion for the score was
greater than 6, this questionnaire had a sensitivity of
93.5%, a specificity of 67.3%, a positive likelihood ratio
of 2.96, and a negative likelihood of 0.096.
Discussion
Patients with cervical myelopathy have various symp-
toms, such as numbness, pain, hypoesthesia and
14
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Figure 1 Histogram showing the distribution of the total
scores in the two groups.
Table 6 Self-administered questionnaire
Assigned
score
Do you have difficulty climbing the stairs to one floor
above?
2
Do you have difficulty walking for 15 minutes? 1
Do you have a feeling of residual urine in your bladder
after voiding?
1
Can you initiate (start) your urine stream immediately
when you want to void?
1
Do you have neck pain, shoulder pain, and neck
stiffness?
2
Do you have chest tightness? 2
Do you have pain or numbness in the upper extremity? 3
Do you have pain or numbness from chest to forefoot? 1
Total score cut-off point: ≥ 6
Sensitivity: 93.5%
Specificity: 67.3%
Positive likelihood ratio: 2.96
Negative likelihood ratio: 0.096
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Figure 2 Receiver operating characteristic (ROC) curves.T h e
arrow shows the cut-off point assigned to 6.
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neck, manual clumsiness, walking disturbance, and urin-
ary disturbance [2-5]. Because upper extremity symp-
toms may be caused by other diseases including cervical
myelopathy, entrapment neuropathy, and diabetes melli-
tus, it is difficult to distinguish between cervical myelo-
pathy and other diseases. The clinical findings of
cervical myelopathy did not have a high sensitivity, so
an experienced physician was required to make the diag-
nosis. Cervical myelopathy is diagnosed based on the
symptoms, neurological findings, and magnetic reso-
nance images. However, there is no gold standard for
cervical myelopathy. It is reported that 20% of patients
with cervical myelopathy have no myelopathic signs,
including Hoffmann’s sign, an inverted brachioradialis
reflex, clonus, and Babinski’s sign [11]. Therefore, a
method to easily screen for cervical myelopathy in pri-
mary care clinics is needed.
In this study, a self-administered questionnaire includ-
ing eight items to screen for cervical myelopathy was
developed. In the present study, the item pool was cho-
sen from JOACMEQ, a self-administered questionnaire
used as an outcome measurement for patients with cer-
vical myelopathy, that was developed using epidemiolo-
gical approaches and has been shown to have validity,
reliability, and responsiveness [6-9]. JOACMEQ consists
of four subgroups: function of the cervical spine, upper
extremities, lower extremities, and bladder. In the ques-
tionnaire developed in this study, items for lower leg
function and urination disorder were included. These
facts suggests that long tract signs are important for
making the diagnosis of cervical myelopathy, which is in
agreement with clinical practice.
When the cut-off point for the total score was set at 6,
the sensitivity was 93.5% and the specificity was 67.3%.
These values are sufficiently high for screening. The posi-
tive likelihood ratio for this questionnaire was 2.96. This
value means that this questionnaire is not useful for mak-
ing a definitive diagnosis of cervical myelopathy. The
negative likelihood was 0.096, which means that this
q u e s t i o n n a i r ei su s e f u lt or u l eo u tt h eo t h e rd i s e a s e s .
Therefore, these results suggest that the questionnaire
developed in this study is useful for cervical myelopathy
screening.
The fact that the patient group comprised only surgical
cases is one of the limitations of this study. To develop
the questionnaire, only surgical cases were included in
the patient group because they had a confirmed diagnosis
of cervical myelopathy. Because this questionnaire is
intended to be used to screen for cervical myelopathy in
the primary care setting, however, a validation study
using a larger group that includes mild, non-surgical
cases of cervical myelopathy is required to test the ques-
tionnaire’s validity and reliability. Another limitation of
this study is that the control group consisted mostly of
patients with peripheral entrapment neuropathy who
underwent surgery; therefore, diseases of various severi-
ties should be evaluated. Despite these limitations, this
new self-administered questionnaire is effective and easy
to use in clinical practice. This questionnaire has only
eight items that fit on 1 A4-sized page and patients can
complete the questionnaire in about 5 min. We expect
that the use of this questionnaire in primary care would
improve the accuracy of cervical myelopathy screening.
Further studies are needed to investigate the accuracy of
this questionnaire in patients with cervical myelopathy of
various degrees of severity.
Conclusion
We developed a simple self-administered questionnaire
to screen for cervical myelopathy in outpatients.
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